Journal of Scleroderma and Related Disorders, published by SAGE Publications Ltd, stands as a key platform dedicated to advancing the understanding of scleroderma and related autoimmune disorders. With its ISSN of 2397-1983 and E-ISSN of 2397-1991, this esteemed journal has been contributing to the field since its inception in 2016 and continues to attract attention with its convergence period extending to 2024. The journal operates with an open access policy, thus enhancing the visibility and accessibility of research findings for healthcare professionals, researchers, and students worldwide. Recognized for its significant impact, it holds a Q3 quartile ranking in Immunology and Q2 rankings in Immunology and Allergy and Rheumatology in 2023, showcasing its relevance in these critical fields. Furthermore, the journal has achieved commendable Scopus rankings, positioning it firmly within the top echelons of its categories, particularly in Medicine - Rheumatology (#33/73, 55th percentile). With its comprehensive scope, the Journal of Scleroderma and Related Disorders plays a pivotal role in disseminating vital research that can influence treatment strategies and improve patient care for those suffering from scleroderma and its related conditions.

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

The Lancet Rheumatology, published by Elsevier, is a premier academic journal dedicated to advancing the understanding of rheumatology and immunological diseases. Launched in 2019, this esteemed publication has quickly become a leading source of research, achieving an impressive Q1 ranking in both the fields of Rheumatology and Immunology as of 2023. With Scopus rankings placing it at #2 out of 73 in Medicine - Rheumatology and #6 out of 233 in Medicine - Immunology and Allergy, the journal serves as an essential platform for disseminating high-quality, peer-reviewed articles that address the latest findings and clinical practices in these domains. The journal, accessible in print and online, is committed to fostering knowledge and collaboration among researchers, healthcare professionals, and students alike, making it an invaluable resource for those seeking to deepen their expertise in rheumatology and its interrelated fields.

Advances in Rheumatology is a premier open-access journal published by BMC, dedicated to advancing the field of rheumatology through high-quality, peer-reviewed research. Launched in 2018, the journal has quickly established itself within the academic community, achieving a commendable Q2 ranking in the category of Rheumatology as of 2023 and ranking #34 out of 73 in the Scopus Medicine Rheumatology listings, placing it in the 54th percentile. With a focus on innovative treatments, patient care, and the latest in rheumatological research, the journal provides a platform for researchers and clinicians to disseminate their findings and foster collaborative advancements in this critical area of medicine. Recognized for its accessibility, the journal follows an open-access model, ensuring that research is freely available to a global audience. With a commitment to high standards of academic rigor, Advances in Rheumatology plays a vital role in enhancing the understanding and treatment of rheumatic diseases, making it an invaluable resource for researchers, professionals, and students alike.

Current Opinion in Rheumatology, published by Lippincott Williams & Wilkins, stands as a vital resource in the field of rheumatology. Since its inception in 1989, this prestigious journal has been at the forefront of disseminating cutting-edge research, with a notable Q1 ranking in the 2023 Rheumatology category and an impressive Scopus rank of 7 out of 73, placing it in the 91st percentile. The journal's commitment to presenting insightful reviews and critical analyses of recent advancements and treatment strategies makes it an essential read for professionals, researchers, and students dedicated to the study of rheumatic diseases. Although not an open-access journal, Current Opinion in Rheumatology continues to foster an informed dialogue within the academic community through its high-impact content, ensuring that the latest developments and practices are accessible to those at the vanguard of rheumatology research.

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.

LUPUS is a premier peer-reviewed journal published by SAGE Publications Ltd, focusing on the field of rheumatology, with a specific emphasis on the complexities of lupus and related autoimmune disorders. Since its inception in 1991, the journal has consistently ranked in the Q2 category within the rheumatology field, currently positioned as #29 out of 73 in Scopus, reflecting its significant contributions to research and clinical practice. The journal aims to foster a deeper understanding of lupus through the publication of original research articles, reviews, and clinical studies, making it an essential resource for researchers, clinicians, and students dedicated to advancing knowledge in this vital area of medicine. With an impact factor that underscores its influence, LUPUS serves as a critical platform for sharing innovative findings and engaging discussions within the global scientific community. Although the journal follows a traditional access model, it is situated in the United Kingdom, at 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, and remains dedicated to supporting the continuous advancement of research in autoimmune diseases.

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.